TABLE 1.
Compound | Strain | Cell | IC50 (nM)* | CC50 (μM)# |
Formycin A | A/WSN/33 | MDCK | 37.3 ± 21.5 | |
MDCK | 2.77 ± 0.17 | |||
SMeFM | A/WSN/33 | MDCK | 34.1 ± 27.4 | |
A/equine/2/Miami/63 | MDCK | 43.8 ± 27.7 | ||
B/Lee/40 | MDCK | 37.9 ± 26.6 | ||
MDCK | 14.6 ± 9.7 | |||
A/WSN/33 | A549 | 52.4 ± 1.1 | ||
A549 | 20.8 ± 7.7 | |||
A/WSN/33 | Calu-3 | 24.4 ± 6.3 | ||
Calu-3 | 145.8 ± 41.5 | |||
T-705 | A/WSN/33 | MDCK | 200.3 ± 11.7 | |
MDCK | >1,000 |
*The half-maximal inhibitory concentration (IC50) was determined from the result of the plaque assay. Average values with standard deviations from three independent experiments were shown.
#The half-maximal cytotoxic concentration (CC50) was determined from the result of the MTS assay.
Average values with standard deviations from three independent experiments were shown.